How to Get GLP-1 in New York (2026): Costs, Coverage and Telehealth Options | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you live in New York and you have been searching how to get a GLP-1 prescription, the answer is simpler than the ad copy makes it look — but the cost math is messier. New York Medicaid (NYRx) excludes GLP-1 medications for weight loss under 18 NYCRR § 505.3(g)(3); commercial coverage depends on your employer’s formulary; Medicare still doesn’t cover anti-obesity drugs in 2026. That leaves four legitimate routes for most New Yorkers: a primary care doctor, an obesity medicine specialist, a New York–licensed telehealth platform, or a local NYC clinic. This guide walks each path, the actual cash-pay numbers as of 2026, and where PlexusDx Weight Management Protocols — including the Microdose GLP-1 Protocol at $129/mo, Semaglutide Injection at $149/mo, and Tirzepatide Injection at $249/mo — sit relative to FDA-approved branded options like Wegovy and Zepbound. PlexusDx ships compounded GLP-1s to all 50 states, and yes — that includes New York.

Is telehealth GLP-1 prescribing legal in New York?

Yes. New York law allows telehealth prescribing of GLP-1 medications when the prescribing clinician holds a valid New York medical license and the evaluation meets the same clinical standards as an in-person visit. That means a structured intake, review of relevant medical history, and an appropriate follow-up cadence. New York is not one of the five states where PlexusDx requires a scheduled live consultation rather than async intake — if you are a New York resident, you can complete a PlexusDx intake online and a licensed clinician reviews your eligibility for any of the six Weight Management Protocols. That includes Semaglutide Oral for patients who prefer a daily tablet over a weekly injection, and Tirzepatide Oral for patients who want the dual GIP/GLP-1 mechanism without needles.

The four legitimate paths to a GLP-1 prescription in New York

Path 1 — New York–licensed telehealth. The fastest cash-pay route. National platforms serving New York include Ro, Hims/Hers, GoodRx Care, Walgreens Weight Management, and PlexusDx. Async intake, prescription within days, medication shipped to your door. Cash pricing in 2026 ranges from $129/mo (PlexusDx Microdose GLP-1 Protocol) on the low end to $499+/mo for FDA-approved branded Zepbound through retail pharmacy channels.

Path 2 — Your primary care doctor. Best for patients who want their existing PCP to manage prescribing, prior authorization, and follow-up. Strongest path if your commercial insurance covers Wegovy or Zepbound — your PCP’s office submits the prior auth and you pay your copay. Slowest path if you don’t have insurance coverage; office visits, lab fees, and full retail medication cost stack up quickly.

Path 3 — An obesity medicine specialist. Board-certified obesity medicine physicians bring deeper experience with titration, side-effect management, and long-term maintenance. Expect higher visit fees ($300–$600 for an initial consult in NYC) and the same insurance and medication cost dynamics as Path 2.

Path 4 — NYC in-person clinics. Quality at NYC clinics varies. Pricing ranges from $200–$600+ per visit before medication. Verify the prescribing clinician’s New York license at nysed.gov/professions before booking; verify any compounded medication is dispensed through a licensed U.S. compounding pharmacy.

What you will actually pay in New York — cash-pay 2026 numbers

For New Yorkers without GLP-1 insurance coverage, here is the realistic cash-pay landscape. Wegovy oral (semaglutide pill), FDA-approved for weight loss in late 2025 and launched January 2026, runs $149–$299/mo through manufacturer direct programs and select telehealth routes. Wegovy injection at brand list runs roughly $1,000–$1,350/mo before insurance, with manufacturer self-pay programs cutting that for eligible patients. Zepbound (tirzepatide) at brand list is similar; Lilly Direct’s self-pay vials run roughly $499/mo for eligible patients. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo across five dose levels, Semaglutide Oral from $249/mo across six dose levels, Tirzepatide Injection at $249/mo across six dose levels, Tirzepatide Oral at $279/mo across seven dose levels, and GLP-Squared dual-compound at $249/mo. All-inclusive pricing — async clinician consultation, prescription, compounded medication, and shipping to New York — with no membership fee.

Does New York Medicaid cover GLP-1 for weight loss? (No.)

NYRx, New York’s Medicaid pharmacy program, does not cover GLP-1 receptor agonists when the indication is weight loss. The exclusion is codified at 18 NYCRR § 505.3(g)(3) and applies to Wegovy, Zepbound, and Saxenda for chronic weight management. NYRx does cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza) when standard prior-authorization criteria are met. Federal CMS rules may expand Medicaid anti-obesity coverage starting in mid-2026 if New York opts in; track NYS Department of Health bulletins for updates. For Medicaid patients in New York who want GLP-1 weight-loss treatment in 2026, cash-pay is the realistic option — and PlexusDx’s entry-tier Microdose GLP-1 Protocol at $129/mo is the lowest-cost compounded option in the PlexusDx catalog.

Commercial insurance and Medicare in New York

Roughly one in five large-employer plans covered GLP-1s for weight loss in 2025, with the trend upward heading into 2026. Call your insurer using the number on the back of your card and ask three questions: (1) Does my plan cover Wegovy and/or Zepbound for chronic weight management? (2) What are the prior-authorization criteria (BMI, comorbidities, prior attempts)? (3) What is my copay or coinsurance once approved? Medicare Part D does not currently cover anti-obesity medications; a CMS pilot is anticipated for mid-2026 but is not yet active. HSA and FSA funds qualify for GLP-1 medication costs, telehealth consultations, and associated lab work in New York under standard IRS Section 213(d) rules.

Compounded vs FDA-approved branded GLP-1 in New York

This is the substantive medication-source choice and it is worth understanding before you sign up. FDA-approved branded GLP-1 medications — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Trulicity, Victoza — are the finished drug products that ran the SUSTAIN, STEP, and SURMOUNT clinical trials. Compounded semaglutide and tirzepatide — what PlexusDx and many other cash-pay platforms dispense — are pharmacy-prepared formulations of the same active ingredients, prepared by licensed U.S. compounding pharmacies under FDA compounding regulations. Compounded GLP-1s are not FDA-approved finished products; the FDA does not review them for safety, effectiveness, or quality before dispensing. With the national semaglutide and tirzepatide injection shortages now officially resolved, the FDA’s enforcement stance on mass-market compounded GLP-1s has tightened. PlexusDx sources only from licensed U.S. compounding pharmacies, but every patient considering compounded GLP-1 should discuss the specific risks with their prescribing clinician.

Why genetics matter before your first dose

GLP-1 response varies meaningfully across patients, and the variation is partly genetic. Variants in GLP1R (the GLP-1 receptor itself), GIPR (rs1800437 is the headline variant for differential GLP-1 response), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights — so the prescribing clinician can anchor titration decisions to your biology rather than starting from a population-average schedule. Available standalone for $298, or as a $99 add-on after your first month on any PlexusDx Weight Management Protocol.

Side effects, safety, and the boxed warning

All GLP-1 agonists (and tirzepatide, a GIP/GLP-1 dual agonist) share a well-characterized profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common, especially during the first 4–8 weeks and after each dose escalation. Less common but documented: pancreatitis, gallbladder disease, and acute kidney injury. The boxed warning for thyroid C-cell tumors applies to BOTH semaglutide AND tirzepatide based on rodent studies; patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take either medication. Discuss your full medical history with your prescribing clinician before starting any GLP-1.

How to spot a legitimate New York GLP-1 provider

The cash-pay GLP-1 market has attracted bad actors. Before you give a website your credit card or your medical history, verify the basics. (1) Confirm the prescribing clinician holds a current New York medical license at nysed.gov/professions. (2) Confirm the medication is sourced from a licensed U.S. pharmacy (compounding pharmacies should be 503A or 503B registered with state and federal regulators). (3) Confirm there is a real medical intake, an actual prescription written by an actual clinician, and a follow-up schedule. (4) Confirm pricing is transparent — no custom-price gimmicks. (5) Avoid any site that sells GLP-1 without a prescription, uses research-use-only language, or makes guaranteed-results claims. PlexusDx publishes flat pricing and routes New York orders through New York–authorized clinicians.

Frequently asked questions

Can I get a GLP-1 prescription online in New York?

Yes. Multiple New York–licensed telehealth platforms prescribe GLP-1 medications through online intake and virtual visits. PlexusDx serves New York with async intake; the prescribing clinician must hold a current New York medical license. You do not need to visit a doctor’s office for the initial prescription on most cash-pay platforms.

Is telehealth GLP-1 prescribing legal in New York?

Yes. New York permits telehealth prescribing of GLP-1 medications when the prescribing clinician holds a valid New York medical license and the evaluation meets the same standards as an in-person visit. New York is not one of the five states where PlexusDx requires a scheduled live consultation; New York residents complete a PlexusDx intake online.

What is the cheapest way to get GLP-1 in New York?

If your commercial insurance covers Wegovy or Zepbound at a low copay, that is typically the cheapest path. If you are cash-pay, the lowest-cost compounded option in the PlexusDx catalog is the Microdose GLP-1 Protocol at $129/mo flat — all-inclusive of clinician consultation, compounded medication, and shipping. FDA-approved Wegovy oral starts around $149/mo through manufacturer direct programs.

Does New York Medicaid cover Wegovy or Zepbound for weight loss?

No. NYRx excludes GLP-1 medications when prescribed for weight loss under 18 NYCRR § 505.3(g)(3). NYRx does cover GLP-1s for type 2 diabetes when standard prior-authorization criteria are met. Federal expansion of Medicaid anti-obesity coverage may begin mid-2026 if New York opts in.

Is compounded semaglutide legal in New York?

Compounded semaglutide is not an FDA-approved finished product. It must be prescribed by a licensed clinician and dispensed by a licensed compounding pharmacy. The FDA does not review compounded GLP-1s for safety, effectiveness, or quality before dispensing. With the national semaglutide injection shortage now officially resolved, FDA enforcement against mass-market compounded GLP-1 products has increased. Discuss the specific risks with your prescribing clinician.

What is the difference between Wegovy and Zepbound?

Both are FDA-approved for chronic weight management. Wegovy contains semaglutide and targets the GLP-1 receptor only. Zepbound contains tirzepatide and targets both GIP and GLP-1 receptors (dual agonist). In trials, Zepbound showed slightly greater average weight loss at the highest doses (about 20% vs about 15%). Cost, availability, and insurance coverage differ; PlexusDx offers compounded versions of both as Semaglutide Injection and Tirzepatide Injection.

Can I use my HSA or FSA for GLP-1 in New York?

Yes. GLP-1 medications, telehealth consultations, and associated lab work qualify as eligible medical expenses under most HSA and FSA plans for New York residents under standard IRS Section 213(d) rules. Save your receipts and any clinician notes documenting the indication.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Semaglutide Cost, Tirzepatide Costs, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for Wegovy, Zepbound, Ro, and other providers referenced is based on each provider's published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.